HOME > TOP STORIES

TOP STORIES

REGULATORY Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More

January 30, 2020
REGULATORY Japan Ups Responses against Wuhan Coronavirus as First Domestic Transmission Confirmed

January 29, 2020
INTERVIEW “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician

January 28, 2020
REGULATORY Discussions on Off-Year Re-Pricing to Begin in Spring, Focus on Scope of Drugs, Impact on Stakeholders: MHLW Bureau Chief

January 27, 2020
REGULATORY ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials

January 24, 2020
REGULATORY Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing

January 23, 2020
REGULATORY Get Serious about Reviewing Scope of Health Coverage, Says MOF Budget Examiner

January 22, 2020
REGULATORY Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana

January 22, 2020
REGULATORY Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash

January 21, 2020
BUSINESS Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise

January 20, 2020
BUSINESS Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist

January 20, 2020
REGULATORY MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues

January 17, 2020
ACADEMIA Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain

January 16, 2020
BUSINESS Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz

January 15, 2020
BUSINESS Astellas, Adaptimmune Hook Up on Off-the-Shelf Cell Therapies

January 15, 2020
REGULATORY Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule

January 14, 2020
BUSINESS Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience

January 10, 2020
BUSINESS Keytruda Top New Sales Generator in 2020, Enhertu Seen as Biggest Arrival: Evaluate

January 9, 2020
BUSINESS Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market

January 8, 2020
ORGANIZATION As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage

January 7, 2020

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…